High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic
Neuro-Oncology · 2025
DOI: 10.1093/neuonc/noaf035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Dannielle H Upton und 21 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Fenretinide, Brain Neoplasms, Glioma, High-Throughput Screening Assays. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council, Cure Brain Cancer Foundation.
Abstract (Originalsprache)
Background
Diffuse midline glioma, characterized by H3K27 alteration (DMG), is the predominant high-grade glioma in children. It commonly originates in the brainstem, yet effective treatments for these patients remain elusive.
Methods
To identify novel therapies for DMG, we conducted high-throughput drug screens (HTS) using biologically active, clinically approved compounds against DMG neurospheres. Multiple primary DMG cultures were utilized in conjunction with in vitro cytotoxicity and clonogenic assays to validate the efficacy of top compounds. Molecularly diverse patient-derived and transgenic DMG orthotopic models were employed to assess therapeutic efficacy alongside pharmacokinetic and immunohistochemical analyses. Mechanistic studies, including RNA sequencing, western blotting, and flow cytometry, were conducted to elucidate the antitumor efficacy of the most promising compound, fenretinide, in DMG cells.
Results
Through HTS, 6 compounds were identified and validated for their potent cytotoxic activity. However, most of these compounds failed to improve survival in an orthotopic Diffuse Midline Glioma (DMG) model due to limited blood-brain barrier (BBB) penetration. In contrast, fenretinide exhibited effective BBB penetration, significantly enhancing the survival of tumor-bearing animals. Mechanistic studies revealed that fenretinide increased reactive oxygen species (ROS) generation and induced apoptosis by inhibiting PDGFRα. RNA-sequencing further elucidated that fenretinide upregulates the Unfolded Protein Response (UPR) and endoplasmic reticulum (ER) stress pathways while downregulating neurogenesis. The in vivo antitumor efficacy of 2 fenretinide formulations was demonstrated in PDGFRα-amplified and transgenic DMG models.
Conclusion
This comprehensive study has identified new DMG therapeutic vulnerabilities and highlights fenretinide as a brain-penetrant, anti-DMG agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.
- Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.
- Alma Mater Studiorum University of Bologna, Department of Pharmacy and Biotechnology, Bologna, Italy.
- Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
- Kid's Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.
ORCID-Profile: Santosh Valvi, Han Shen, Maria Tsoli
Förderung
- National Health and Medical Research Council
- Cure Brain Cancer Foundation
Zitieren
APA
Upton, D. H., Liu, J., George, S. M., Valvi, S., Ung, C., Rayner, B. S., Gopalakrishnan, A., Pandher, R., Khan, A., Venkat, P., Mayoh, C., Holliday, H., Yeung, N., Nguyen, H., Franshaw, L., Ehteda, A., Shen, H., Farruggia, G., Orienti, I., …, & Ziegler, D. S. (2025). High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf035
Vancouver
Upton DH, Liu J, George SM, Valvi S, Ung C, Rayner BS, et al. High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf035
BibTeX
@article{Upton2025,
author = {Upton, Dannielle H and Liu, Jie and George, Sandra M and Valvi, Santosh and Ung, Caitlin and Rayner, Benjamin S and Gopalakrishnan, Anjana and Pandher, Ruby and Khan, Aaminah and Venkat, Pooja and Mayoh, Chelsea and Holliday, Holly and Yeung, Nicole and Nguyen, Hieu and Franshaw, Laura and Ehteda, Anahid and Shen, Han and Farruggia, Giovanna and Orienti, Isabella and Reynolds, C Patrick and Tsoli, Maria and Ziegler, David S},
title = {High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic},
journal = {Neuro-Oncology},
year = {2025},
doi = {10.1093/neuonc/noaf035}
}
EUVIMED